{
    "nct_id": "NCT06673069",
    "title": "A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)",
    "status": "ACTIVE_NOT_RECRUITING",
    "last_update_time": "2025-09-08",
    "description_brief": "The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.",
    "description_detailed": "This is a phase 1b multi-center, open-label, single ascending dose (SAD) study in adult participants with Down syndrome with evidence of brain amyloid positivity. Participants will be examined in 3 separate cohorts and will receive a single dose of study drug during the 36-week treatment period, followed by a 4-week follow-up period.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "ION269 \u2014 an RNA-targeted antisense oligonucleotide (ASO) intended to reduce APP expression and thereby lower amyloid production"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial description and sponsor material indicate ION269 is an RNA-targeted investigational therapeutic from Ionis being tested in adults with Down syndrome with brain amyloid positivity; the Down syndrome rationale is reducing overexpression of APP (on chromosome 21) to decrease amyloid pathology, which is a disease-modifying approach rather than a symptomatic cognitive enhancer or neuropsychiatric treatment. \ue200cite\ue202turn0search5\ue202turn0search3\ue201",
        "Act: Evidence from the trial listings shows the study (Hero Study, Phase 1b) is sponsored by Ionis and evaluates safety/tolerability of ION269 in amyloid\u2011positive adults with Down syndrome; institutional trial summaries describe the drug as aiming to reduce APP production. These sources identify ION269 as an antisense oligonucleotide (RNA\u2011targeted) therapeutic, which fits the \"biologic\" category (nucleic\u2011acid biologic) targeting Alzheimer\u2019s pathology. \ue200cite\ue202turn0search0\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: Classification as a \"disease-targeted biologic\" aligns with the definition (biologics that target AD pathology such as amyloid/tau). ION269 is not a small molecule, nor described as a symptomatic cognitive enhancer or behavioral treatment. If you want, I can fetch the official ClinicalTrials.gov record or Ionis scientifc materials (protocol/press release) for additional details (dose, mechanism text, trial design). \ue200cite\ue202turn0search9\ue202turn0search5\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational ION269 is described in sponsor and site materials as an RNA\u2011targeted antisense oligonucleotide (ASO) intended to reduce APP expression in adults with Down syndrome in order to lower amyloid production and brain amyloid burden. This explicitly targets the amyloid precursor protein / amyloid\u2011\u03b2 pathway. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Extracted facts \u2014 drug: ION269; modality: antisense oligonucleotide (RNA\u2011targeted biologic); intended mechanism: reduce APP mRNA/protein to decrease amyloid\u2011\u03b2 generation; indication/context: amyloid\u2011positive adults with Down syndrome (trisomy 21, APP overexpression). These points are documented in the trial listings and institutional summaries. \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Reflect: Reducing APP to lower A\u03b2 production is a disease\u2011modifying strategy directed at amyloid biology, which matches CADRO category A (Amyloid beta). Literature on APP\u2011targeting ASOs in DS/APP\u2011duplication models supports this mechanism as an anti\u2011amyloid approach. No competing target (e.g., tau, inflammation, synaptic function) is described, so 'A) Amyloid beta' is the most specific fit. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Web search results (selected sources used): IonisTrials Hero study listing (ION269) \u2014 Hero: A Study to Evaluate the Safety, Tolerability, and PK/PD of ION269 in Participants With Down Syndrome. \ue200cite\ue202turn0search0\ue201; University Hospitals trial summary for ION269 (Ionis DS) \u2014 describes APP overexpression rationale. \ue200cite\ue202turn0search3\ue201; CenterWatch / trial registries summarizing Hero (NCT06673069) and study design. \ue200cite\ue202turn0search6\ue201; Brain / PubMed publications showing APP\u2011targeting ASOs reduce A\u03b2 and aggregates in DS/APP duplication models. \ue200cite\ue202turn0search5\ue202turn0search7\ue201"
    ]
}